Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a β-blocker)

International Journal of Cardiology

Volumn 93, Issue 2-3, 2004, Pages 105-111

  Dimopoulos, Konstantinos ^a,b   Salukhe, Tushar V ^a,b   Coats, Andrew J S ^a,c   Mayet, Jamil ^a,d   Piepoli, Massimo ^a,e   Francis, Darrel P ^a,d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ST MARY S HOSPITAL   (United Kingdom)

^e Ospedale Civile di Piacenza   (Italy)

Author keywords

Angiotensin receptor II antagonists; Heart failure; Meta analysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; LOSARTAN; QUINAPRIL; RAMIPRIL; VALSARTAN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFECT; FOLLOW UP; HEART FAILURE; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 1242272211     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.10.001     Document Type: Article

References (27)

1. Hedges L.V., Olkin I. Statistical methods for meta-analysis. 1985;Academic Press, San Diego. Chapter 5.
2. Cochran W.G. The combination of estimates from different experiments. Biometrics. 10:1954;101-129.
3. Hamroff G., Katz S.D., Mancini D.et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 99:1999;990-992.
4. McKelvie R.S., Yusuf S., Pericak D.et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 100:1999;1056-1064.
5. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345:2001;1667-1675.
6. McMurray J.J., Ostergren J., Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 362:2003;767-771.
7. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch. Intern. Med. 153:1993;937-942.
8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 353:1999;9-13.
9. Packer M., Bristow M.R., Cohn J.N.et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334:1996;1349-1355.
10. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 353:1999;2001-2007.
11. Pitt B., Zannad F., Remme W.J.et al. The effect of spironolactone in morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341:1999;709-717.
12. Williams S.G., Cooke G.A., Wright D.J., Tan L.B. Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a reappraisal of vasodilator therapy and study design. Int. J. Cardiol. 77:2001;239-245.
13. Harjai K.J., Solis S., Prasad A., Loupe J. Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure. Int. J. Cardiol. 88:2003;207-214.
14. Rousseau M.F., Konstam M.A., Benedict C.R.et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am. J. Cardiol. 73:1994;488-493.
15. Francis G.S., Cohn J.N., Johnson G., Rector T.S., Goldman S., Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation. 87(Suppl VI):1993;VI-40-VI-48.
16. Jorde U.P., Ennezat P.V., Lisker J.et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 101:2000;844-846.
17. St. John Sutton M., Pfeffer M.A., Moye L.et al. Cardio-vascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation. 96:1997;3294-3299.
18. Willenheimer R., Helmers C., Pantev E., Rydberg E., Lofdahl P., Gordon A. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int. J. Cardiol. 85:2002;261-270.
19. Pitt B., Poole-Wilson P.A.et al. Effect of Losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 355:2000;1582-1587.
20. Sharma D., Buyse M., Pitt B., Rucinska E.J. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. Am. J. Cardiol. 85:2000;187-192.
21. Coats A.J. Angiotensin receptor blockers - finally the evidence is coming in: IDNT and RENAAL. Int. J. Cardiol. 79:2001;99-102.
22. Azizi M., Chatellier G., Guyene T.T.et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 92:1995;825-834.
23. Wollert K.C., Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc. Res. 43:1999;838-849.
24. Yu G., Liang X., Xie X., Su M., Zhao S. Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats. Int. J. Cardiol. 81:2001;123-129.
25. Jong P., Demers C., McKelvie R.S., Liu P.P. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. Am. Coll. Cardiol. 39:2002;463-470.
26. Barki-Harrington L., Luttrell L.M., Rockman H.A. Dual inhibition of {beta}-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation. 108:2003;r79-r86.
27. J.N. Cohn,Val-HeFT efficacy subgroup analyses (presentation). US Food and Drug Administration Web site. Available at www.fda.gov/ohrms/dockets/ac/01/ slides/3793s1_03_efficacy%20subgroups.pdf.